This may be a glimmer of hope for the 17,000 patients who reported side effects because of the new Levothyrox formula : Tirosint (TCAPS in France), has just obtained a marketing authorization from the National Agency for Health Products and Medicines (ANSM). A new alternative that, according to information from the Parisian , should be marketed by the laboratory in February, February 2018.

Formulated with levothyroxine, the same active ingredient as the old formula Levothyrox, TCAPS, is in the form of soft capsules and is the sole excipient of glycerin. It has already been offered in some European countries and in the United States for several years.

Another alternative for patients with side effects

Until then, patients with thyroid disorders and suffering from side effects could turn to three other drugs: the L-Thyroxine from the Serb laboratory (oral solution in drops primarily reserved for children under 8 years, to people with swallowing disorders and to patients who have already had a prescription of this specialty before August 31, 2017), Sanofi's L-Thyroxin Henning (tablets) and Unipharma's Thyrofix (tablets).

A diversification of the offer promised by Agnès Buzyn, Minister of Solidarities and Health, in September 2017 "to put an end to the monopoly on this drug," she explained at the microphone of RMC. "The important thing is that patients have the choice (...) I can understand their distress (...) We have made sure there are different offers of medicines for thyroid disorders. They are already available in Europe and will arrive on the French market, which will allow people to find the formula that suits them, "she added.

To report any adverse effects: www.signalement-sante.gouv.fr.